novartis.com is a domain that was created on 1996-04-02,making it 28 years ago. It has several subdomains, such as campus.novartis.com pharma.us.novartis.com , among others.
Description:Working together, we can reimagine medicine to improve and extend people’s...
Discover novartis.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
HomePage size: 271.39 KB |
Page Load Time: 0.049469 Seconds |
Website IP Address: 104.18.1.16 |
Novartis United States of America pharma.us.novartis.com |
Home - Novartis novartis.horizonblue.com |
Novartis contactus.novartisoncology.us |
Novartis https://www.novartis.com/ |
Investors https://www.novartis.com/investors |
Novartis Data Exchange Hompage https://securemail.novartis.com/ |
Careers https://www.novartis.com/careers |
Manufacturing https://www.novartis.com/about/manufacturing |
Stories https://www.novartis.com/stories |
ESG https://www.novartis.com/esg |
Novartis Event Platform https://virtual.novartis.com/ |
Enroll in the Novartis Oncology Universal Co-pay Program https://copay.novartis.com/ |
Novartis United States of America https://www.novartis.com/us-en/ |
Products | Novartis https://www.novartis.com/about/products |
About | Novartis https://www.novartis.com/about |
Product Portfolio | Novartis United States of America https://www.novartis.com/us-en/about/products |
News | Novartis https://www.novartis.com/news |
Novartis in the US | Novartis United States of America https://www.novartis.com/us-en/about/novartis-us |
A novartis.com. 21600 IN A 104.18.0.16 |
MX novartis.com. 310 IN MX 10 mx07-0019ad02.pphosted.com. |
NS novartis.com. 1800 IN NS dns3.novartis.com. |
TXT novartis.com. 86400 IN TXT 8gIsxbea3/jTooWjVqLOLXM5+5rvApkxSEISqdEEuKY= |
SOA novartis.com. 21600 IN SOA dns1.novartis.com. hostmaster.novartis.com. 2024051103 28800 7200 604800 3600 |
Date: Tue, 14 May 2024 04:11:49 GMT |
Content-Type: text/html; charset=UTF-8 |
Transfer-Encoding: chunked |
Connection: keep-alive |
Cache-Control: public, max-age=18000 |
content-language: en |
x-content-type-options: nosniff |
x-frame-options: SAMEORIGIN |
expires: Tue, 14 May 2024 09:11:49 GMT |
last-modified: Tue, 14 May 2024 04:10:27 GMT |
vary: Cookie,Accept-Encoding |
content-security-policy-report-only: "script-src self unsafe-inline unsafe-eval https://unpkg.com https://acsbapp.com https://snap.licdn.com https://maps.googleapis.com https://static.ads-twitter.com https://analytics.twitter.com https://connect.facebook.net https://cdn.cookielaw.org https://www.youtube.com https://static.addtoany.com https://cdnjs.cloudflare.com https://www.googletagmanager.com https://js-agent.newrelic.com https://geolocation.onetrust.com https://bam-cell.nr-data.net https://cdnsecakmi.kaltura.com https://cdnapisec.kaltura.com http://cdnapi.kaltura.com https://www.google-analytics.com https://cdn.jsdelivr.net https://script.crazyegg.com https://static.cloudflareinsights.com https://www.google.com https://www.gstatic.com https://bam.nr-data.net https://hm.baidu.com/hm.js blob:; object-src self unsafe-inline unsafe-eval https: data; style-src self unsafe-inline unsafe-eval https://cdn.cookielaw.org https://acsbapp.com https://maps.googleapis.com https://fonts.googleapis.com https://www.youtube.com https://static.addtoany.com https://cdnjs.cloudflare.com https://www.googletagmanager.com https://js-agent.newrelic.com https://geolocation.onetrust.com https://bam-cell.nr-data.net https://script.crazyegg.com https://static.cloudflareinsights.com https://cdnapisec.kaltura.com; frame-ancestors self; report-uri /report-csp-violation", x-xss-protection: 1; mode=block |
strict-transport-security: max-age=31536000; includeSubDomains |
x-request-id: v-e52e128a-11a7-11ef-8511-876cfd7b2c70 |
x-ah-environment: prod |
via: varnish |
x-cache: HIT |
x-cache-hits: 12 |
CF-Cache-Status: HIT |
Server: cloudflare |
CF-RAY: 88380be12ae05edf-PDX |
charset="utf-8"/ |
content="Working together, we can reimagine medicine to improve and extend people’s lives." name="description"/ |
content="Working together, we can reimagine medicine to improve and extend people’s lives." name="abstract"/ |
content="Novartis" property="og:site_name"/ |
content="Website" property="og:type"/ |
content="https://www.novartis.com/home" property="og:url"/ |
content="Novartis" property="og:title"/ |
content="Working together, we can reimagine medicine to improve and extend people’s lives." property="og:description"/ |
content="https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif" property="og:image"/ |
content="https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif" property="og:image:url"/ |
content="https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif" property="og:image:secure_url"/ |
content="Novartis logo" property="og:image:alt"/ |
content="summary_large_image" name="twitter:card"/ |
content="Working together, we can reimagine medicine to improve and extend people’s lives." name="twitter:description"/ |
content="@novartis" name="twitter:site"/ |
content="Novartis" name="twitter:title"/ |
content="17226612" name="twitter:site:id"/ |
content="@novartis" name="twitter:creator"/ |
content="17226612" name="twitter:creator:id"/ |
content="https://www.novartis.com/home" name="twitter:url"/ |
content="https://www.novartis.com/sites/novartis_com/files/novartis-logo-open-graph.jpg" name="twitter:image"/ |
content="Novartis logo" name="twitter:image:alt"/ |
content="" name="google-site-verification"/ |
content="width" name="MobileOptimized"/ |
content="true" name="HandheldFriendly"/ |
content="width=device-width, initial-scale=1, shrink-to-fit=no" name="viewport"/ |
content="ie=edge" http-equiv="x-ua-compatible"/ |
Search Global | en Choose Location International Americas Asia Pacific Europe Middle East & Africa Global | English Foundation | English Argentina | Español Brazil | Português Canada | English Canada | Français Central America | Español Colombia | Español Mexico | Español United States | English Australia | English Bangladesh | English Hong Kong S.A.R. | 繁體中文 India | English Indonesia | English Japan | 日本語 Korea | 한국어 Mainland China | 中文 Malaysia | English Pakistan | English Philippines | English Singapore | English Taiwan | 繁體中文 Thailand | ภาษาไทย Austria | Deutsch Belgium | Français Belgium | Nederlands Bulgaria | Български Czech Republic | Česky Czech Republic | English Denmark | Dansk Estonia | Eesti Finland | Suomalainen France | Français Germany | Deutsch Greece | Ελληνικά Hungary | Magyar Ireland | English Italy | Italiano Latvia | Latvian Lithuania | Lithuanian Netherlands | Nederlands Norway | Norsk Poland | Polski Portugal | Português Romania | Română Russia | Русский Serbia | Srpski Slovakia | Slovensky Slovenia | Slovenščina Slovenia | English Spain | Español Sweden | Svenska Switzerland | Deutsch Switzerland | Français Türkiye | Türkçe United Kingdom | English Egypt | English Israel | עברית Saudi Arabia | العربية South Africa | English Global Choose Location international International Americas Asia Pacific Europe Middle East & Africa Argentina | Español Australia | English Austria | Deutsch Bangladesh | English Belgium | Français Belgium | Nederlands Brazil | Português Bulgaria | Български Canada | English Canada | Français Central America | Español Colombia | Español Czech Republic | Česky Czech Republic | English Denmark | Dansk Egypt | English Estonia | Eesti Finland | Suomalainen France | Français Germany | Deutsch Greece | Ελληνικά Hong Kong S.A.R. | 繁體中文 Hungary | Magyar India | English Indonesia | English Ireland | English Israel | עברית Italy | Italiano Japan | 日本語 Korea | 한국어 Latvia | Latvian Lithuania | Lithuanian Mainland China | 中文 Malaysia | English Mexico | Español Netherlands | Nederlands Norway | Norsk Global | English Foundation | English Pakistan | English Philippines | English Poland | Polski Portugal | Português Romania | Română Russia | Русский Saudi Arabia | العربية Serbia | Srpski Singapore | English Slovakia | Slovensky Slovenia | Slovenščina Slovenia | English South Africa | English Spain | Español Sweden | Svenska Switzerland | Deutsch Switzerland | Français Taiwan | 繁體中文 Thailand | ภาษาไทย Türkiye | Türkçe United Kingdom | English United States | English Menu About Board of Directors Joerg Reinhardt Simon Moroney Nancy C. Andrews Ton Buechner Patrice Bula Elizabeth (Liz) Doherty Ana de Pro Gonzalo Bridgette Heller Daniel Hochstrasser Frans van Houten Charles L. Sawyers William T. Winters John D. Young Charlotte Pamer-Wieser Executive Committee Vasant (Vas) Narasimhan Shreeram Aradhye Victor Bulto Aharon (Ronny) Gal Karen L. Hale Patrick Horber Harry Kirsch Rob Kowalski Steffen Lang Fiona Marshall Klaus Moosmayer Lutz Hegemann Kees Roks Michelle Weese Products Therapeutic areas Cardiovascular, renal and metabolic Immunology Neuroscience Oncology People and culture Diversity, equity and inclusion Equity Inclusivity Parental leave Society Gene Therapies Manufacturing Quality Audit program quality management system (QMS) Product and patient safety training Regulatory inspections Product recalls Third-party suppliers Awards and recognition About is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Patients and caregivers commitment to patients and caregivers Diseases Patient organization funding Patients perspectives stories Patients and caregivers Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting. Healthcare professionals Medical congresses and events Abstract summaries for EULAR Abstract summaries for ACR ASCO annual meeting Products pipeline Managed access programs Gene Therapies managed access program external funding Healthcare professional resources by country Investigator-initiated trials / studies medical information Submit medical enquiry Healthcare professionals Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information. Research and development Technology platforms Research disease areas Cardiovascular and metabolic disease research at DAx: exploratory disease research at Global Health disease area research at Immunology disease research at Neuroscience research at Oncology research at Ophthalmology research at pipeline Research collaborations Collaborations Research & development Discover how turns breakthrough science into transformative, high-value treatments. ESG Access Creating sustainable business models Value-based pricing Sub-Saharan Africa Donations access principles oncology access Patents and licensing Environmental sustainability Climate Waste Water Ethics, risk and compliance Ethical behavior Compliance Human rights Learning and engagement Risk management Global health Pandemic preparedness Avoidable blindness Chagas disease Leprosy Malaria Sickle cell disease (SCD) Foundation Diversity, equity and inclusion ESG index Reporting and transparency hub in Society Integrated Report ESG rating performance Targets Patient organization funding Payments to healthcare professionals Public policy A living wage A safe workplace Animal research Environmental, social and governance Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the in Society Integrated Report. Investors Event calendar Financial data annual results quarterly results SEC filings Product sales Fixed-income securities Expected currency impact Share data and analysis Share monitor Dividend information Share ownership Share overview Return on investment calculator Shareholder information General Meetings American Depositary Receipts (ADR) Share buyback Frequently asked questions Company overview Corporate governance Reporting and transparency hub in Society Integrated Report Reporting archive ESG rating performance Publications order form ESG Investors Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting. News News archive Media library Stories Subscribe News Information for journalists including media releases, statements, stories, multimedia resources and more. Careers Career search Our business functions Careers in research and development Careers in operations Careers in commercial and sales Careers in global functions Why Career hub Temporary contracts Early careers Graduates Students US Biomedical Research internship programs Community exploration and learning lab (CELL) Careers is hiring! Find open positions, learn more about our strategy and culture, and apply today. Clinical trials Partnering Supplier portal Report side effects Contacts Home Working together, we can reimagine medicine to improve and extend people’s lives. Header Reimagining medicine together Working together, we can reimagine medicine to improve and extend people’s lives. Discover our medicines Our innovative medicines address society’s greatest disease burdens and restore possibility for patients. Explore our science Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives. Learn about our impact Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective. Financial Results – Q1 2024 announced...
Domain Name: NOVARTIS.COM Registry Domain ID: 2845657_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.markmonitor.com Registrar URL: http://www.markmonitor.com Updated Date: 2022-10-16T09:03:11Z Creation Date: 1996-04-02T05:00:00Z Registry Expiry Date: 2024-11-17T17:29:14Z Registrar: MarkMonitor Inc. Registrar IANA ID: 292 Registrar Abuse Contact Email: abusecomplaints@markmonitor.com Registrar Abuse Contact Phone: +1.2086851750 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Domain Status: serverDeleteProhibited https://icann.org/epp#serverDeleteProhibited Domain Status: serverTransferProhibited https://icann.org/epp#serverTransferProhibited Domain Status: serverUpdateProhibited https://icann.org/epp#serverUpdateProhibited Name Server: A1-254.AKAM.NET Name Server: A2-66.AKAM.NET Name Server: A24-65.AKAM.NET Name Server: A28-67.AKAM.NET Name Server: A7-64.AKAM.NET Name Server: A9-65.AKAM.NET Name Server: DNS1.NOVARTIS.COM Name Server: DNS2.NOVARTIS.COM Name Server: DNS3.NOVARTIS.COM Name Server: DNS4.NOVARTIS.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T19:10:10Z <<<